Tarsus Pharmaceuticals, Inc.
TARS
Kedudukan dalam Saham
#4589
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Harga Saham
$71.12
Modal Pasaran
$3.33B
Perubahan (1 hari)
2.33%
Perubahan (1 tahun)
-0.10%
Negara
US
Perdagangan Tarsus Pharmaceuticals, Inc. (TARS)
Kategori
Healthcare
Sejarah pecahan saham untuk Tarsus Pharmaceuticals, Inc. (TARS)
Saham Tarsus Pharmaceuticals, Inc. (simbol: TARS) telah mengalami sejumlah 0 pecahan saham.
Pecahan saham terkini berlaku pada Oct 20, 2026.
Satu saham TARS yang dibeli sebelum Oct 20, 2026 kini bersamaan dengan 0 saham TARS.
Pecahan saham terkini berlaku pada Oct 20, 2026.
Satu saham TARS yang dibeli sebelum Oct 20, 2026 kini bersamaan dengan 0 saham TARS.
Senarai pecahan saham
| Tahun | Pecahan | Gandaan | Gandaan Kumulatif |
|---|---|---|---|
| Tidak cukup data untuk tarikh yang disediakan. | |||
Pecahan saham untuk syarikat pesaing atau serupa
| Syarikat | Bilangan pecahan saham | Gandaan Kumulatif | Negara |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
